Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
VistaGen Therapeutics ( (VTGN) ) just unveiled an update.
On June 2, 2025, Vistagen Therapeutics announced that its PALISADE-3 Phase 3 clinical trial for fasedienol, aimed at treating social anxiety disorder, is on track for topline data release in the fourth quarter of 2025. The PALISADE-4 trial is expected to yield results in the first half of 2026. These trials are part of Vistagen’s efforts to establish fasedienol’s effectiveness for a potential New Drug Application submission to the U.S. FDA. The trials incorporate strategic enhancements to replicate the success of the PALISADE-2 trial, which reported positive results in 2023.
The most recent analyst rating on (VTGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.
Spark’s Take on VTGN Stock
According to Spark, TipRanks’ AI Analyst, VTGN is a Underperform.
VistaGen Therapeutics faces significant financial difficulties, with substantial losses and negative cash flows, which are major risk factors. The technical analysis indicates a bearish trend, compounded by an unattractive valuation due to its negative P/E ratio. While the earnings call highlighted progress in clinical trials and a strong cash position, the increased R&D expenses and net loss are concerns. Overall, the stock remains speculative with significant challenges ahead.
To see Spark’s full report on VTGN stock, click here.
More about VistaGen Therapeutics
Vistagen, headquartered in South San Francisco, CA, is a late clinical-stage biopharmaceutical company focusing on neuroscience with nose-to-brain neurocircuitry. The company is developing a new class of intranasal therapies called pherines, which are designed to rapidly activate olfactory bulb-to-brain neurocircuits without requiring absorption into the blood or uptake into the brain. Vistagen aims to provide transformative treatment options for conditions like social anxiety disorder, major depressive disorder, and women’s health issues.
Average Trading Volume: 131,086
Technical Sentiment Signal: Sell
Current Market Cap: $74.46M
For an in-depth examination of VTGN stock, go to TipRanks’ Stock Analysis page.